Loading…
Reported covered position: Government Relations Director
How to read the money
Income and expense are whole-filing amounts associated with this lobbyist, not personal compensation or an allocated share.
No topic inference: each bill number appears in source LDA issue text assigned to this lobbyist.
Antibiotic Development to Advance Patient Treatment Act
Client: INFECTIOUS DISEASES SOCIETY OF AMERICA · Firm: INFECTIOUS DISEASES SOCIETY OF AMERICA
Infectious diseases (generally, no specific legislation); drug, diagnostics and vaccine R&D (generally, no specific legislation); antimicrobial resistance (generally, no specific legislation); antimicrobial stewardship (generally, no specific legislation); hospital-acquired infections (generally, no specific legislation); immunizations (generally, no specific legislation); pandemic influenza, public health security and biodefense (generally, no specific legislation); global infectious diseases (generally, no specific legislation); biomedical research (generally, no specific legislation); reauthorization of the President's Emergency Plan for AIDS Relief (PEPFAR) (generally, no specific legislation); Lyme diseases and other infectious diseases issues (generally, no specific legislation); Ryan White reauthorization (generally, no specific legislation); Prescription Drug User Fee Act (PDUFA)(generally, no specific legislation); Antibiotic Development to Advance Patient Treatment (ADAPT) Act (HR 2629); Developing an Innovative Strategy for Antimicrobial Resistant Microorganisms (DISARM) Act (HR 512); Promise for Antibiotics and Therapeutics for Health (PATH) Act (S.185); Preventing Antibiotic Resistance Act (PARA)(S.621)
Specific issues are shown only where the LDA source assigned them to this lobbyist. Targets apply to the associated filing.
INFECTIOUS DISEASES SOCIETY OF AMERICA via INFECTIOUS DISEASES SOCIETY OF AMERICA
2016 · fourth_quarter · Q4
Reimbursement for outpatient infusion therapy (generally, no specific legislation); physician payments (generally, no specific legislation); Medicaid and Medicare, including Medicare Prescription Drug Coverage (generally, no specific legislation); Average Sales Price (generally, no specific legislation); Competitive Acquisition Program (generally, no specific legislation); infection control (generally, no specific legislation); antimicrobial stewardship (generally, no specific legislation); Healthcare Reform (generally, no specific legislation).
Source: Senate LDA
Antibiotic Development to Advance Patient Treatment Act
Client: INFECTIOUS DISEASES SOCIETY OF AMERICA · Firm: INFECTIOUS DISEASES SOCIETY OF AMERICA
Infectious diseases (generally, no specific legislation); drug, diagnostics and vaccine R&D (generally, no specific legislation); antimicrobial resistance (generally, no specific legislation); antimicrobial stewardship (generally, no specific legislation); hospital-acquired infections (generally, no specific legislation); immunizations (generally, no specific legislation); pandemic influenza, public health security and biodefense (generally, no specific legislation); global infectious diseases (generally, no specific legislation); biomedical research (generally, no specific legislation); reauthorization of the President's Emergency Plan for AIDS Relief (PEPFAR) (generally, no specific legislation); Lyme diseases and other infectious diseases issues (generally, no specific legislation); Ryan White reauthorization (generally, no specific legislation); Prescription Drug User Fee Act (PDUFA)(generally, no specific legislation); Antibiotic Development to Advance Patient Treatment (ADAPT) Act (HR 2629); Developing an Innovative Strategy for Antimicrobial Resistant Microorganisms (DISARM) Act (HR 512); Promise for Antibiotics and Therapeutics for Health (PATH) Act (S.185); Preventing Antibiotic Resistance Act (PARA)(S.621)
DISARM Act of 2015
Client: INFECTIOUS DISEASES SOCIETY OF AMERICA · Firm: INFECTIOUS DISEASES SOCIETY OF AMERICA
Infectious diseases (generally, no specific legislation); drug, diagnostics and vaccine R&D (generally, no specific legislation); antimicrobial resistance (generally, no specific legislation); antimicrobial stewardship (generally, no specific legislation); hospital-acquired infections (generally, no specific legislation); immunizations (generally, no specific legislation); pandemic influenza, public health security and biodefense (generally, no specific legislation); global infectious diseases (generally, no specific legislation); biomedical research (generally, no specific legislation); reauthorization of the President's Emergency Plan for AIDS Relief (PEPFAR) (generally, no specific legislation); Lyme diseases and other infectious diseases issues (generally, no specific legislation); Ryan White reauthorization (generally, no specific legislation); Prescription Drug User Fee Act (PDUFA)(generally, no specific legislation); Antibiotic Development to Advance Patient Treatment (ADAPT) Act (HR 2629); Developing an Innovative Strategy for Antimicrobial Resistant Microorganisms (DISARM) Act (HR 512); Promise for Antibiotics and Therapeutics for Health (PATH) Act (S.185); Preventing Antibiotic Resistance Act (PARA)(S.621)
DISARM Act of 2015
Client: INFECTIOUS DISEASES SOCIETY OF AMERICA · Firm: INFECTIOUS DISEASES SOCIETY OF AMERICA
Infectious diseases (generally, no specific legislation); drug, diagnostics and vaccine R&D (generally, no specific legislation); antimicrobial resistance (generally, no specific legislation); antimicrobial stewardship (generally, no specific legislation); hospital-acquired infections (generally, no specific legislation); immunizations (generally, no specific legislation); pandemic influenza, public health security and biodefense (generally, no specific legislation); global infectious diseases (generally, no specific legislation); biomedical research (generally, no specific legislation); reauthorization of the President's Emergency Plan for AIDS Relief (PEPFAR) (generally, no specific legislation); Lyme diseases and other infectious diseases issues (generally, no specific legislation); Ryan White reauthorization (generally, no specific legislation); Prescription Drug User Fee Act (PDUFA)(generally, no specific legislation); Antibiotic Development to Advance Patient Treatment (ADAPT) Act (HR 2629); Developing an Innovative Strategy for Antimicrobial Resistant Microorganisms (DISARM) Act (HR 512); Promise for Antibiotics and Therapeutics for Health (PATH) Act (S.185); Preventing Antibiotic Resistance Act (PARA)(S.621)
PATH Act
Client: INFECTIOUS DISEASES SOCIETY OF AMERICA · Firm: INFECTIOUS DISEASES SOCIETY OF AMERICA
Infectious diseases (generally, no specific legislation); drug, diagnostics and vaccine R&D (generally, no specific legislation); antimicrobial resistance (generally, no specific legislation); antimicrobial stewardship (generally, no specific legislation); hospital-acquired infections (generally, no specific legislation); immunizations (generally, no specific legislation); pandemic influenza, public health security and biodefense (generally, no specific legislation); global infectious diseases (generally, no specific legislation); biomedical research (generally, no specific legislation); reauthorization of the President's Emergency Plan for AIDS Relief (PEPFAR) (generally, no specific legislation); Lyme diseases and other infectious diseases issues (generally, no specific legislation); Ryan White reauthorization (generally, no specific legislation); Prescription Drug User Fee Act (PDUFA)(generally, no specific legislation); Antibiotic Development to Advance Patient Treatment (ADAPT) Act (HR 2629); Developing an Innovative Strategy for Antimicrobial Resistant Microorganisms (DISARM) Act (HR 512); Promise for Antibiotics and Therapeutics for Health (PATH) Act (S.185); Preventing Antibiotic Resistance Act (PARA)(S.621)
PATH Act
Client: INFECTIOUS DISEASES SOCIETY OF AMERICA · Firm: INFECTIOUS DISEASES SOCIETY OF AMERICA
Infectious diseases (generally, no specific legislation); drug, diagnostics and vaccine R&D (generally, no specific legislation); antimicrobial resistance (generally, no specific legislation); antimicrobial stewardship (generally, no specific legislation); hospital-acquired infections (generally, no specific legislation); immunizations (generally, no specific legislation); pandemic influenza, public health security and biodefense (generally, no specific legislation); global infectious diseases (generally, no specific legislation); biomedical research (generally, no specific legislation); reauthorization of the President's Emergency Plan for AIDS Relief (PEPFAR) (generally, no specific legislation); Lyme diseases and other infectious diseases issues (generally, no specific legislation); Ryan White reauthorization (generally, no specific legislation); Prescription Drug User Fee Act (PDUFA)(generally, no specific legislation); Antibiotic Development to Advance Patient Treatment (ADAPT) Act (HR 2629); Developing an Innovative Strategy for Antimicrobial Resistant Microorganisms (DISARM) Act (HR 512); Promise for Antibiotics and Therapeutics for Health (PATH) Act (S.185); Preventing Antibiotic Resistance Act (PARA)(S.621)
Preventing Antibiotic Resistance Act of 2015
Client: INFECTIOUS DISEASES SOCIETY OF AMERICA · Firm: INFECTIOUS DISEASES SOCIETY OF AMERICA
Infectious diseases (generally, no specific legislation); drug, diagnostics and vaccine R&D (generally, no specific legislation); antimicrobial resistance (generally, no specific legislation); antimicrobial stewardship (generally, no specific legislation); hospital-acquired infections (generally, no specific legislation); immunizations (generally, no specific legislation); pandemic influenza, public health security and biodefense (generally, no specific legislation); global infectious diseases (generally, no specific legislation); biomedical research (generally, no specific legislation); reauthorization of the President's Emergency Plan for AIDS Relief (PEPFAR) (generally, no specific legislation); Lyme diseases and other infectious diseases issues (generally, no specific legislation); Ryan White reauthorization (generally, no specific legislation); Prescription Drug User Fee Act (PDUFA)(generally, no specific legislation); Antibiotic Development to Advance Patient Treatment (ADAPT) Act (HR 2629); Developing an Innovative Strategy for Antimicrobial Resistant Microorganisms (DISARM) Act (HR 512); Promise for Antibiotics and Therapeutics for Health (PATH) Act (S.185); Preventing Antibiotic Resistance Act (PARA)(S.621)
Preventing Antibiotic Resistance Act of 2015
Client: INFECTIOUS DISEASES SOCIETY OF AMERICA · Firm: INFECTIOUS DISEASES SOCIETY OF AMERICA
Infectious diseases (generally, no specific legislation); drug, diagnostics and vaccine R&D (generally, no specific legislation); antimicrobial resistance (generally, no specific legislation); antimicrobial stewardship (generally, no specific legislation); hospital-acquired infections (generally, no specific legislation); immunizations (generally, no specific legislation); pandemic influenza, public health security and biodefense (generally, no specific legislation); global infectious diseases (generally, no specific legislation); biomedical research (generally, no specific legislation); reauthorization of the President's Emergency Plan for AIDS Relief (PEPFAR) (generally, no specific legislation); Lyme diseases and other infectious diseases issues (generally, no specific legislation); Ryan White reauthorization (generally, no specific legislation); Prescription Drug User Fee Act (PDUFA)(generally, no specific legislation); Antibiotic Development to Advance Patient Treatment (ADAPT) Act (HR 2629); Developing an Innovative Strategy for Antimicrobial Resistant Microorganisms (DISARM) Act (HR 512); Promise for Antibiotics and Therapeutics for Health (PATH) Act (S.185); Preventing Antibiotic Resistance Act (PARA)(S.621)
Creation of tax credits to incentivize R&D of new antibiotics for serious and life threatening drug-resistant infections (generally, no specific legislation); related new rapid diagnostic tests (generally, no specific legislation).
Medical liability (generally, no specific legislation); antimicrobial resistance research (generally, no specific legislation); infectious diseases product R&D (generally, no specific legislation); regulatory science (generally, no specific legislation); unnecessary regulatory burdens placed on medical research (generally, no specific legislation); laboratory developed tests (generally, no specific legislation); comparative effectiveness research (generally, no specific legislation); support for evidence-based decision making (generally, no specific legislation); point-of-care diagnostic tests (generally, no specific legislation); and organ transplant policy to allow HIV+ to HIV+ organ transplants (generally, no specific legislation).
Infectious diseases (generally, no specific legislation); drug, diagnostics and vaccine R&D (generally, no specific legislation); antimicrobial resistance (generally, no specific legislation); antimicrobial stewardship (generally, no specific legislation); hospital-acquired infections (generally, no specific legislation); immunizations (generally, no specific legislation); pandemic influenza, public health security and biodefense (generally, no specific legislation); global infectious diseases (generally, no specific legislation); biomedical research (generally, no specific legislation); reauthorization of the President's Emergency Plan for AIDS Relief (PEPFAR) (generally, no specific legislation); Lyme diseases and other infectious diseases issues (generally, no specific legislation); Ryan White reauthorization (generally, no specific legislation); Prescription Drug User Fee Act (PDUFA)(generally, no specific legislation); Antibiotic Development to Advance Patient Treatment (ADAPT) Act (HR 2629); Developing an Innovative Strategy for Antimicrobial Resistant Microorganisms (DISARM) Act (HR 512); Promise for Antibiotics and Therapeutics for Health (PATH) Act (S.185); Preventing Antibiotic Resistance Act (PARA)(S.621)
Funding support for the Department of Health and Human Services, Office of the Biomedical Advanced Research and Development Authority, Centers for Disease Control and Prevention, National Institutes of Health, Health Resources and Services Administration, Food and Drug Administration and global programs for various infectious diseases related issues.
Filing targets: Agency for Healthcare Research & Quality (AHRQ), Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), Natl Institutes of Health (NIH), SENATE
INFECTIOUS DISEASES SOCIETY OF AMERICA via INFECTIOUS DISEASES SOCIETY OF AMERICA
2016 · third_quarter · Q3
Reimbursement for outpatient infusion therapy (generally, no specific legislation); physician payments (generally, no specific legislation); Medicaid and Medicare, including Medicare Prescription Drug Coverage (generally, no specific legislation); Average Sales Price (generally, no specific legislation); Competitive Acquisition Program (generally, no specific legislation); infection control (generally, no specific legislation); antimicrobial stewardship (generally, no specific legislation); Healthcare Reform (generally, no specific legislation).
Infectious diseases (generally, no specific legislation); drug, diagnostics and vaccine R&D (generally, no specific legislation); antimicrobial resistance (generally, no specific legislation); antimicrobial stewardship (generally, no specific legislation); hospital-acquired infections (generally, no specific legislation); immunizations (generally, no specific legislation); pandemic influenza, public health security and biodefense (generally, no specific legislation); global infectious diseases (generally, no specific legislation); biomedical research (generally, no specific legislation); reauthorization of the President's Emergency Plan for AIDS Relief (PEPFAR) (generally, no specific legislation); Lyme diseases and other infectious diseases issues (generally, no specific legislation); Ryan White reauthorization (generally, no specific legislation); Prescription Drug User Fee Act (PDUFA)(generally, no specific legislation); Antibiotic Development to Advance Patient Treatment (ADAPT) Act (HR 2629); Developing an Innovative Strategy for Antimicrobial Resistant Microorganisms (DISARM) Act (HR 512); Promise for Antibiotics and Therapeutics for Health (PATH) Act (S.185); Preventing Antibiotic Resistance Act (PARA)(S.621)
Funding support for the Department of Health and Human Services, Office of the Biomedical Advanced Research and Development Authority, Centers for Disease Control and Prevention, National Institutes of Health, Health Resources and Services Administration, Food and Drug Administration and global programs for various infectious diseases related issues.
Creation of tax credits to incentivize R&D of new antibiotics for serious and life threatening drug-resistant infections (generally, no specific legislation); related new rapid diagnostic tests (generally, no specific legislation).
Medical liability (generally, no specific legislation); antimicrobial resistance research (generally, no specific legislation); infectious diseases product R&D (generally, no specific legislation); regulatory science (generally, no specific legislation); unnecessary regulatory burdens placed on medical research (generally, no specific legislation); laboratory developed tests (generally, no specific legislation); comparative effectiveness research (generally, no specific legislation); support for evidence-based decision making (generally, no specific legislation); point-of-care diagnostic tests (generally, no specific legislation); and organ transplant policy to allow HIV+ to HIV+ organ transplants (generally, no specific legislation).
Filing targets: Agency for Healthcare Research & Quality (AHRQ), Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), Natl Institutes of Health (NIH), SENATE
INFECTIOUS DISEASES SOCIETY OF AMERICA via INFECTIOUS DISEASES SOCIETY OF AMERICA
2016 · second_quarter · Q2
Creation of tax credits to incentivize R&D of new antibiotics for serious and life threatening drug-resistant infections; related new rapid diagnostic tests
Infectious diseases; drug, diagnostics and vaccine R&D; antimicrobial resistance; antimicrobial stewardship; hospital-acquired infections; immunizations; pandemic influenza, public health security and biodefense; global infectious diseases; biomedical research; reauthorization of PEPFAR; Lyme diseases and other infectious diseases issues; Ryan White reauthorization; PDUFA; ADAPT Act; DISARM Act; PATH Act; PARA Act
Reimbursement for outpatient infusion therapy; physician payments; Medicaid and Medicare, including Medicare Prescription Drug Coverage; Average Sales Price; Competitive Acquisition Program; infection control; antimicrobial stewardship; Healthcare Reform
Funding support for the Department of Health and Human Services, Office of the Biomedical Advanced Research and Development Authority, Centers for Disease Control and Prevention, National Institutes of Health, Health Resources and Services Administration, Food and Drug Administration and global programs for various infectious diseases related issues.
Medical liability; antimicrobial resistance research; infectious diseases product R&D; regulatory science; unnecessary regulatory burdens placed on medical research; laboratory developed tests; comparative effectiveness research; support for evidence-based decision making; point-of-care diagnostic tests; and organ transplant policy to allow HIV+ to HIV+ organ transplants
Filing targets: Agency for Healthcare Research & Quality (AHRQ), Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), Natl Institutes of Health (NIH), SENATE
INFECTIOUS DISEASES SOCIETY OF AMERICA via INFECTIOUS DISEASES SOCIETY OF AMERICA
2016 · first_quarter · Q1
Infectious diseases; drug, diagnostics and vaccine R&D; antimicrobial resistance; antimicrobial stewardship; hospital-acquired infections; immunizations; pandemic influenza, public health security and biodefense; global infectious diseases; biomedical research; reauthorization of PEPFAR; Lyme diseases and other infectious diseases issues; Ryan White reauthorization; PDUFA; ADAPT Act; DISARM Act; PATH Act; PARA Act
Funding support for the Department of Health and Human Services, Office of the Biomedical Advanced Research and Development Authority, Centers for Disease Control and Prevention, National Institutes of Health, Health Resources and Services Administration, Food and Drug Administration and global programs for various infectious diseases related issues.
Reimbursement for outpatient infusion therapy; physician payments; Medicaid and Medicare, including Medicare Prescription Drug Coverage; Average Sales Price; Competitive Acquisition Program; infection control; antimicrobial stewardship; Healthcare Reform
Medical liability; antimicrobial resistance research; infectious diseases product R&D; regulatory science; unnecessary regulatory burdens placed on medical research; laboratory developed tests; comparative effectiveness research; support for evidence-based decision making; point-of-care diagnostic tests; and organ transplant policy to allow HIV+ to HIV+ organ transplants
Creation of tax credits to incentivize R&D of new antibiotics for serious and life threatening drug-resistant infections; related new rapid diagnostic tests
Filing targets: Agency for Healthcare Research & Quality (AHRQ), Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), Natl Institutes of Health (NIH), SENATE
INFECTIOUS DISEASES SOCIETY OF AMERICA via INFECTIOUS DISEASES SOCIETY OF AMERICA
2015 · fourth_quarter · Q4
Infectious diseases; drug, diagnostics and vaccine R&D; antimicrobial resistance; antimicrobial stewardship; hospital-acquired infections; immunizations; pandemic influenza, public health security and biodefense; global infectious diseases; biomedical research; reauthorization of PEPFAR; Lyme diseases and other infectious diseases issues; Ryan White reauthorization; PDUFA; ADAPT Act; DISARM Act; PATH Act; PARA Act
Reimbursement for outpatient infusion therapy; physician payments; Medicaid and Medicare, including Medicare Prescription Drug Coverage; Average Sales Price; Competitive Acquisition Program; infection control; antimicrobial stewardship; Healthcare Reform
Funding support for the Department of Health and Human Services, Office of the Biomedical Advanced Research and Development Authority, Centers for Disease Control and Prevention, National Institutes of Health, Health Resources and Services Administration, Food and Drug Administration and global programs for various infectious diseases related issues.
Creation of tax credits to incentivize R&D of new antibiotics for serious and life threatening drug-resistant infections; related new rapid diagnostic tests
Medical liability; antimicrobial resistance research; infectious diseases product R&D; regulatory science; unnecessary regulatory burdens placed on medical research; laboratory developed tests; comparative effectiveness research; support for evidence-based decision making; point-of-care diagnostic tests; and organ transplant policy to allow HIV+ to HIV+ organ transplants
Filing targets: Agency for Healthcare Research & Quality (AHRQ), Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), Natl Institutes of Health (NIH), SENATE
INFECTIOUS DISEASES SOCIETY OF AMERICA via INFECTIOUS DISEASES SOCIETY OF AMERICA
2015 · third_quarter · Q3
Reimbursement for outpatient infusion therapy; physician payments; Medicaid and Medicare, including Medicare Prescription Drug Coverage; Average Sales Price; Competitive Acquisition Program; infection control; antimicrobial stewardship; Healthcare Reform
Creation of tax credits to incentivize R&D of new antibiotics for serious and life threatening drug-resistant infections; related new rapid diagnostic tests
Infectious diseases; drug, diagnostics and vaccine R&D; antimicrobial resistance; antimicrobial stewardship; hospital-acquired infections; immunizations; pandemic influenza, public health security and biodefense; global infectious diseases; biomedical research; reauthorization of PEPFAR; Lyme diseases and other infectious diseases issues; Ryan White reauthorization; PDUFA; ADAPT Act; DISARM Act; PATH Act; PARA Act
INFECTIOUS DISEASES SOCIETY OF AMERICA via INFECTIOUS DISEASES SOCIETY OF AMERICA
2015 · second_quarter · Q2
Infectious diseases; drug, diagnostics and vaccine R&D; antimicrobial resistance; antimicrobial stewardship; hospital-acquired infections; immunizations; pandemic influenza, public health security and biodefense; global infectious diseases; biomedical research; reauthorization of PEPFAR; Lyme diseases and other infectious diseases issues; Ryan White reauthorization; PDUFA; ADAPT Act; DISARM Act; PATH Act; PARA Act
Creation of tax credits to incentivize R&D of new antibiotics for serious and life threatening drug-resistant infections; related new rapid diagnostic tests
INFECTIOUS DISEASES SOCIETY OF AMERICA via INFECTIOUS DISEASES SOCIETY OF AMERICA
2015 · first_quarter · Q1
Creation of tax credits to incentivize R&D of new antibiotics for serious and life threatening drug-resistant infections; related new rapid diagnostic tests
Reimbursement for outpatient infusion therapy; physician payments; Medicaid and Medicare, including Medicare Prescription Drug Coverage; Average Sales Price; Competitive Acquisition Program; infection control; antimicrobial stewardship; Healthcare Reform
Funding support for the Department of Health and Human Services, Office of the Biomedical Advanced Research and Development Authority, Centers for Disease Control and Prevention, National Institutes of Health, Health Resources and Services Administration, Food and Drug Administration and global programs for various infectious diseases related issues.
INFECTIOUS DISEASES SOCIETY OF AMERICA via INFECTIOUS DISEASES SOCIETY OF AMERICA
2014 · fourth_quarter · Q4
Reimbursement for outpatient infusion therapy; physician payments; Medicaid and Medicare, including Medicare Prescription Drug Coverage; Average Sales Price; Competitive Acquisition Program; infection control; antimicrobial stewardship; and Healthcare Reform.
Infectious diseases; drug, diagnostics and vaccine R&D; antimicrobial resistance; antimicrobial stewardship; hospital-acquired infections; immunizations; pandemic influenza, public health security and biodefense; global infectious diseases; biomedical research; reauthorization of PEPFAR; Lyme disease and other infectious diseases issues; Ryan White reauthorization; PAMTA; GAIN Act; STAAR Act; PDUFA; ADAPT Act, DISARM Act, Diagnostic Innovation Testing and Knowledge Advancement Act
INFECTIOUS DISEASES SOCIETY OF AMERICA via INFECTIOUS DISEASES SOCIETY OF AMERICA
2014 · third_quarter · Q3
Reimbursement for outpatient infusion therapy; physician payments; Medicaid and Medicare, including Medicare Prescription Drug Coverage; Average Sales Price; Competitive Acquisition Program; infection control; antimicrobial stewardship; and Healthcare Reform.
Creation of tax credits to incentivize research and development of new antibiotics for serious and life threatening drug-resistant infections; related new rapid diagnostic tests
Medical liability; antimicrobial resistance research; infectious diseases product research and development; regulatory science; unnecessary regulatory burdens placed on medical research; laboratory developed tests; comparative effectiveness research; support for evidence-based decision making; point-of-care diagnostic tests; and organ transplant policy to allow HIV+ to HIV+ organ transplants.
INFECTIOUS DISEASES SOCIETY OF AMERICA via INFECTIOUS DISEASES SOCIETY OF AMERICA
2014 · second_quarter · Q2
Creation of tax credits to incentivize research and development of new antibiotics for serious and life threatening drug-resistant infections; related new rapid diagnostic tests
Funding support for the Department of Health and Human Services, Office of the Biomedical Advanced Research and Development Authority, Centers for Disease Control and Prevention, National Institutes of Health, Health Resources & Services Administration, Food & Drug Administration and global programs for various infectious diseases related issues.
Infectious diseases; drug, diagnostics and vaccine R&D; antimicrobial resistance; antimicrobial stewardship; hospital-acquired infections; immunizations; pandemic influenza, public health security and biodefense; global infectious diseases; biomedical research; reauthorization of PEPFAR; Lyme disease and other infectious diseases issues; Ryan White reauthorization; PAMTA; GAIN Act; STAAR Act; PDUFA; ADAPT Act, DISARM Act, Diagnostic Innovation Testing and Knowledge Advancement Act
INFECTIOUS DISEASES SOCIETY OF AMERICA via INFECTIOUS DISEASES SOCIETY OF AMERICA
2014 · first_quarter · Q1
Creation of tax credits to incentivize research and development of new antibiotics for serious and life threatening drug-resistant infections; related new rapid diagnostic tests
Infectious diseases; drug, diagnostics and vaccine R&D; antimicrobial resistance; antimicrobial stewardship; hospital-acquired infections; immunizations; pandemic influenza, public health security and biodefense; global infectious diseases; biomedical research; reauthorization of PEPFAR; Lyme disease and other infectious diseases issues; Ryan White reauthorization; PAMTA; GAIN Act; STAAR Act; PDUFA; ADAPT Act, DISARM Act, Diagnostic Innovation Testing and Knowledge Advancement Act
INFECTIOUS DISEASES SOCIETY OF AMERICA via INFECTIOUS DISEASES SOCIETY OF AMERICA
2013 · fourth_quarter · Q4
Funding support for the Department of Health and Human Services, Office of the Biomedical Advanced Research and Development Authority, Centers for Disease Control and Prevention, National Institutes of Health, Health Resources & Services Administration, Food & Drug Administration and global programs for various infectious diseases related issues.
Creation of tax credits to incentivize research and development of new antibiotics for serious and life threatening drug-resistant infections; related new rapid diagnostic tests
Infectious diseases; drug, diagnostics and vaccine R&D; antimicrobial resistance; antimicrobial stewardship; hospital-acquired infections; immunizations; pandemic influenza, public health security and biodefense; global infectious diseases; biomedical research; reauthorization of PEPFAR; Lyme disease and other infectious diseases issues; Ryan White reauthorization; PAMTA; GAIN Act; STAAR Act; PDUFA
INFECTIOUS DISEASES SOCIETY OF AMERICA via INFECTIOUS DISEASES SOCIETY OF AMERICA
2013 · third_quarter · Q3
Medical liability; antimicrobial resistance research; infectious diseases product research and development; regulatory science; unnecessary regulatory burdens placed on medical research; laboratory developed tests; comparative effectiveness research; support for evidence-based decision making; point-of-care diagnostic tests; and organ transplant policy to allow HIV+ to HIV+ organ transplants.
Funding support for the Department of Health and Human Services, Office of the Biomedical Advanced Research and Development Authority, Centers for Disease Control and Prevention, National Institutes of Health, Health Resources & Services Administration, Food & Drug Administration and global programs for various infectious diseases related issues.
Medical liability; antimicrobial resistance research; infectious diseases product R&D; regulatory science; unnecessary regulatory burdens placed on medical research; laboratory developed tests; comparative effectiveness research; support for evidence-based decision making; point-of-care diagnostic tests; and organ transplant policy to allow HIV+ to HIV+ organ transplants
Funding support for the Department of Health and Human Services, Office of the Biomedical Advanced Research and Development Authority, Centers for Disease Control and Prevention, National Institutes of Health, Health Resources and Services Administration, Food and Drug Administration and global programs for various infectious diseases related issues.
Filing targets: Agency for Healthcare Research & Quality (AHRQ), Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), Natl Institutes of Health (NIH), SENATE
Funding support for the Department of Health and Human Services, Office of the Biomedical Advanced Research and Development Authority, Centers for Disease Control and Prevention, National Institutes of Health, Health Resources and Services Administration, Food and Drug Administration and global programs for various infectious diseases related issues.
Reimbursement for outpatient infusion therapy; physician payments; Medicaid and Medicare, including Medicare Prescription Drug Coverage; Average Sales Price; Competitive Acquisition Program; infection control; antimicrobial stewardship; Healthcare Reform
Medical liability; antimicrobial resistance research; infectious diseases product R&D; regulatory science; unnecessary regulatory burdens placed on medical research; laboratory developed tests; comparative effectiveness research; support for evidence-based decision making; point-of-care diagnostic tests; and organ transplant policy to allow HIV+ to HIV+ organ transplants
Filing targets: Agency for Healthcare Research & Quality (AHRQ), Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), Natl Institutes of Health (NIH), SENATE
Medical liability; antimicrobial resistance research; infectious diseases product R&D; regulatory science; unnecessary regulatory burdens placed on medical research; laboratory developed tests; comparative effectiveness research; support for evidence-based decision making; point-of-care diagnostic tests; and organ transplant policy to allow HIV+ to HIV+ organ transplants
Infectious diseases; drug, diagnostics and vaccine R&D; antimicrobial resistance; antimicrobial stewardship; hospital-acquired infections; immunizations; pandemic influenza, public health security and biodefense; global infectious diseases; biomedical research; reauthorization of PEPFAR; Lyme diseases and other infectious diseases issues; Ryan White reauthorization; PDUFA; ADAPT Act; DISARM Act; PATH Act; PARA Act
Filing targets: Agency for Healthcare Research & Quality (AHRQ), Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), Natl Institutes of Health (NIH), SENATE
Medical liability; antimicrobial resistance research; infectious diseases product research and development; regulatory science; unnecessary regulatory burdens placed on medical research; laboratory developed tests; comparative effectiveness research; support for evidence-based decision making; point-of-care diagnostic tests; and organ transplant policy to allow HIV+ to HIV+ organ transplants.
Funding support for the Department of Health and Human Services, Office of the Biomedical Advanced Research and Development Authority, Centers for Disease Control and Prevention, National Institutes of Health, Health Resources & Services Administration, Food & Drug Administration and global programs for various infectious diseases related issues.
Creation of tax credits to incentivize research and development of new antibiotics for serious and life threatening drug-resistant infections; related new rapid diagnostic tests
Filing targets: Agency for Healthcare Research & Quality (AHRQ), Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), Natl Institutes of Health (NIH), SENATE
Infectious diseases; drug, diagnostics and vaccine R&D; antimicrobial resistance; antimicrobial stewardship; hospital-acquired infections; immunizations; pandemic influenza, public health security and biodefense; global infectious diseases; biomedical research; reauthorization of PEPFAR; Lyme disease and other infectious diseases issues; Ryan White reauthorization; PAMTA; GAIN Act; STAAR Act; PDUFA; ADAPT Act, DISARM Act, Diagnostic Innovation Testing and Knowledge Advancement Act
Funding support for the Department of Health and Human Services, Office of the Biomedical Advanced Research and Development Authority, Centers for Disease Control and Prevention, National Institutes of Health, Health Resources & Services Administration, Food & Drug Administration and global programs for various infectious diseases related issues.
Filing targets: Agency for Healthcare Research & Quality (AHRQ), Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), Natl Institutes of Health (NIH), SENATE
Medical liability; antimicrobial resistance research; infectious diseases product research and development; regulatory science; unnecessary regulatory burdens placed on medical research; laboratory developed tests; comparative effectiveness research; support for evidence-based decision making; point-of-care diagnostic tests; and organ transplant policy to allow HIV+ to HIV+ organ transplants.
Reimbursement for outpatient infusion therapy; physician payments; Medicaid and Medicare, including Medicare Prescription Drug Coverage; Average Sales Price; Competitive Acquisition Program; infection control; antimicrobial stewardship; and Healthcare Reform.
Filing targets: Agency for Healthcare Research & Quality (AHRQ), Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), Natl Institutes of Health (NIH), SENATE
Funding support for the Department of Health and Human Services, Office of the Biomedical Advanced Research and Development Authority, Centers for Disease Control and Prevention, National Institutes of Health, Health Resources & Services Administration, Food & Drug Administration and global programs for various infectious diseases related issues.
Reimbursement for outpatient infusion therapy; physician payments; Medicaid and Medicare, including Medicare Prescription Drug Coverage; Average Sales Price; Competitive Acquisition Program; infection control; antimicrobial stewardship; and Healthcare Reform.
Medical liability; antimicrobial resistance research; infectious diseases product research and development; regulatory science; unnecessary regulatory burdens placed on medical research; laboratory developed tests; comparative effectiveness research; support for evidence-based decision making; point-of-care diagnostic tests; and organ transplant policy to allow HIV+ to HIV+ organ transplants.
Filing targets: Agency for Healthcare Research & Quality (AHRQ), Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), Natl Institutes of Health (NIH), SENATE
Medical liability; antimicrobial resistance research; infectious diseases product research and development; regulatory science; unnecessary regulatory burdens placed on medical research; laboratory developed tests; comparative effectiveness research; support for evidence-based decision making; point-of-care diagnostic tests; and organ transplant policy to allow HIV+ to HIV+ organ transplants.
Reimbursement for outpatient infusion therapy; physician payments; Medicaid and Medicare, including Medicare Prescription Drug Coverage; Average Sales Price; Competitive Acquisition Program; infection control; antimicrobial stewardship; and Healthcare Reform.
Filing targets: Agency for Healthcare Research & Quality (AHRQ), Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), Natl Institutes of Health (NIH), SENATE
Infectious diseases; drug, diagnostics and vaccine R&D; antimicrobial resistance; antimicrobial stewardship; hospital-acquired infections; immunizations; pandemic influenza, public health security and biodefense; global infectious diseases; biomedical research; reauthorization of PEPFAR; Lyme disease and other infectious diseases issues; Ryan White reauthorization; PAMTA; GAIN Act; STAAR Act; PDUFA
Reimbursement for outpatient infusion therapy; physician payments; Medicaid and Medicare, including Medicare Prescription Drug Coverage; Average Sales Price; Competitive Acquisition Program; infection control; antimicrobial stewardship; and Healthcare Reform.
Filing targets: Agency for Healthcare Research & Quality (AHRQ), Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), Natl Institutes of Health (NIH), SENATE